Direxion Daily Biotech Top 5 Bull 2X ETF

Gilead Sciences to Present Latest HIV Treatment and Prevention Data at CROI 2026

Ocular Therapeutix's Eye Drug Axpaxli Surpasses Regeneron's Eylea

Qinhao Medicine's GH31 Project Reaches Global Collaboration Agreement with Gilead

Amgen Receives Approval for Uplizna for Use in MG Patients in Europe

Amgen Announces Phase III Study Plans for UPLIZNA and Positive Phase II Results for Daxdilimab

Vertex Pharma released FY2025 Annual Earnings on February 12 After-Market (EST), Actual Revenue: USD 0 (Forecast: USD 11.98 B), Actual EPS: USD 0 (Forecast: USD 15.4939)

Vertex Pharma released FY2025 Q4 earnings on February 12 After-Market EST, actual revenue USD 3.19 B (forecast USD 3.175 B), actual EPS USD 4.6494 (forecast USD 4.588)

Vertex Pharmaceuticals projects 2026 revenue and unveils plans for new drug mid-stage data

JPMorgan Raises Gilead Sciences' Target Price to $160

Gilead Sciences released FY2025 Q4 earnings on February 10 After-Market EST, actual revenue USD 7.925 B (forecast USD 7.678 B), actual EPS USD 1.74 (forecast USD 1.5441)

Gilead Sciences released FY2025 Annual Earnings on February 10 After-Market (EST), Actual Revenue USD 29.44 B (Forecast USD 29.2 B), Actual EPS USD 6.78 (Forecast USD 6.8179)

Gilead Sciences Announces Yeztugo Sales Forecast, Shares Fall

Gilead Sciences Expects Adjusted EPS Range for 2026

Gilead Sciences Reports Biktarvy Sales Growth and Announces Financials with New Drug Launch Plans

Gilead Sciences Announces $32 Billion Investment to Enhance US Operations

Gilead Sciences 2026 Earnings Outlook Affected by Policy Changes

Gilead Announces Q4 Earnings

Vertex Pharmaceuticals to Release Phase 3 Data for Kidney Drug

Amgen Receives FDA Approval for UPLIZNA® to Treat MG Patients

Argus and TipRanks Maintain Buy Rating for Amgen

Algorhythm

Jiade

Moolec Science SA

Nuveen Real Asset Income and Growth Fund

Atomera

AIM ImmunoTech

Splash Beverage

GraniteShares 2x Long RIVN Daily ETF

Founder

Vivopower

TBXU

IBBQ

ARKG

SBIO

Pfizer announced positive results from the BREAKWATER trial, showing that the BRAFTOVI regimen significantly improves progression-free survival in patients with BRAF V600E-mutant metastatic colorectal cancer. The regimen, which combines BRAFTOVI with cetuximab and FOLFIRI, demonstrated meaningful benefits over standard treatments. The results will support potential FDA approval for this investigational treatment. Colorectal cancer remains a major health issue, with BRAF mutations linked to poor prognosis. BRAFTOVI is designed to target the BRAF V600E mutation, addressing a significant unmet need in this patient population.

- The BREAKWATER trial's Cohort 3 analysis showed significant improvement in progression-free survival for patients with BRAF V600E-mutant metastatic colorectal cancer using BRAFTOVI alongside cetuximab and FOLFIRI.  
- Overall survival also exhibited clinically meaningful enhancements, building on previously reported positive response rate data.  
- Pfizer plans to submit detailed trial results to the FDA to support potential approval of this investigational regimen for treating BRAF V600E-mutant metastatic colorectal cancer.

StockTitan

Pfizer

Health Care Select Sector SPDR

iShares Global Healthcare

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

VG Health

Ark Genomic Revolution ETF

iShares Biotechnology ETF

SPDR S&P Biotech

iShares US Pharma

ALPS Medical Breakthrough

Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer | PFE Stock News

Entera welcomes a new chairman to their board, bringing extensive global leadership experience from prominent biopharma companies like Pfizer and Wyeth. The new addition signals Entera's progression as they work towards achieving significant milestones in 2026 with multiple oral peptide programs. This development marks a pivotal moment for Entera as they strive to drive innovation and growth in the biopharmaceutical industry, leveraging the expertise and insights of their new chairman to propel their initiatives forward.

Unusual Whales

Entera Bio

Entera Bio appoints Geno J. Germano as Chairman with Pfizer experience, advancing programs towards 2026 milestones.

VRTX

ABBV

Eli Lilly, AbbVie, Vertex Pharmaceuticals, Gilead Sciences, Pfizer, Abbott Laboratories, and McKesson are highlighted as key pharmaceutical stocks to monitor, according to MarketBeat. These companies have shown significant trading volume recently and are involved in developing and selling various healthcare products. Investors should be aware of the potential risks and rewards associated with these stocks, including drug approvals and regulatory challenges.

- Eli Lilly and Company, along with AbbVie, Vertex Pharmaceuticals, Gilead Sciences, Pfizer, Abbott Laboratories, and McKesson, are highlighted as top pharmaceutical stocks to watch due to high trading volumes.  
- These companies face potential risks from long drug development cycles and regulatory challenges, but they also offer opportunities from successful drug approvals.  
- MarketBeat notes that despite Eli Lilly's Moderate Buy rating, analysts recommend other stocks as better investment options at this time.

Market Beat

Vertex Pharma

Abbvie

Abbott Laboratories

Eli Lilly

McKesson

Gilead Sciences

Direxion Daily LLY Bull 2X Shares

VanEck Pharmaceutical ETF

SPDR Pharmac

Best Pharmaceutical Stocks To Keep An Eye On - February 14th

Wall Street Zen downgraded Alnylam Pharmaceuticals (NASDAQ:ALNY) from a "strong-buy" to a "buy" rating. Other analysts have also adjusted their price targets, with Truist Financial lowering it to $530 and HC Wainwright to $510, both maintaining a "buy" rating. The stock opened at $314.40, with a market cap of $41.54 billion. Alnylam reported $0.82 earnings per share, missing estimates, but revenue increased 84.9% year-over-year. Insiders have sold shares recently, and institutional investors are adjusting their stakes in the company.

Alnylam Pharma

Alnylam Pharmaceuticals (NASDAQ:ALNY) Lowered to "Buy" Rating by Wall Street Zen

Daiwa has downgraded Pfizer (PFE) to a neutral rating after the company's Q4 2025 earnings report, which showed $17.6 billion in revenue and $0.66 EPS, exceeding expectations. Bernstein, however, maintained its Market Perform rating and $30 price target for Pfizer, highlighting it as a promising low-cost stock to buy.

- Pfizer Inc. reported Q4 2025 earnings of $17.6 billion in revenue and $0.66 EPS, exceeding expectations.  
- Bernstein maintained its Market Perform rating and $30 price target for the company.  
- The strong financial results contribute to Pfizer being viewed as a promising low-cost stock to consider for investment.

Daiwa downgrades Pfizer (PFE) to neutral following full-year 2025 earnings

PILL

Bristol Myers Squibb Co. (BMY) shares rose 1.47% to $60.74 on a strong trading day, outperforming competitors like Johnson & Johnson (down 0.45%) and Pfizer (up 0.40%). The S&P 500 Index increased by 0.05%, while the Dow Jones Industrial Average rose 0.10%. Despite the gain, BMY remains 4.09% below its 52-week high of $63.33 reached on March 11. Trading volume was 10.8 million, below the 50-day average of 14.7 million.

- Bristol Myers Squibb Co. (BMY) shares increased by 1.47% to $60.74 during an overall positive trading session, while the S&P 500 and Dow Jones Industrial Average also rose.  
- The stock's gain ended a two-day losing streak and is currently 4.09% below its 52-week high of $63.33 reached on March 11th.  
- Trading volume was 10.8 million, falling short of the 50-day average of 14.7 million.

Dow Jones

Bristol Myers Squibb

Direxion Pharma & Medical Bull 3X

Bristol Myers Squibb Co. Stock Outperforms Competitors On Strong Trading Day

Abbott Laboratories (ABT) shares rose 1.09% to $112.68 on a strong trading day, outperforming some competitors. The S&P 500 Index increased by 0.05%, while the Dow Jones Industrial Average rose by 0.10%. Abbott's stock is currently 20.22% below its 52-week high of $141.23. In comparison, Johnson & Johnson fell 0.45%, Pfizer rose 0.40%, and Merck increased by 1.82%. Trading volume was 7.7 million, below the 50-day average of 9.3 million.

- Abbott Laboratories shares increased by 1.09% to $112.68 during a positive trading session, alongside the S&P 500 and Dow Jones indexes.  
- The stock is currently 20.22% below its 52-week high of $141.23, achieved on March 4th.  
- Trading volume was recorded at 7.7 million, falling short of its 50-day average of 9.3 million.

SPDR S&P 500

Johnson & Johnson

VG S&P 500

iShares US Medical Devices

SPDR S&P Health Equip

Merck

iShares Core S&P 500

Abbott Laboratories Stock Outperforms Competitors On Strong Trading Day

13 analysts have provided varied opinions on Alnylam Pharmaceuticals (NASDAQ:ALNY), with ratings ranging from bullish to bearish. The average 12-month price target is $471.54, down from $502.25. Analysts have adjusted their ratings, with several lowering their price targets. Alnylam has five marketed drugs and shows strong revenue growth of 149.35% as of September 30, 2025. The company has a net margin of 20.1% and a return on equity of 103.65%, but a high debt-to-equity ratio of 5.59 indicates increased financial risk. Analyst ratings are influenced by company performance and market conditions.

benzinga_article

Demystifying Alnylam Pharmaceuticals: Insights From 13 Analyst Reviews

Three stocks have received 'Strong Buy' ratings from top analysts: Grab (GRAB) with a price target of $7.55, implying a 56.07% upside; Alnylam Pharma (ALNY) with a target of $425, suggesting a 56.61% upside; and Datadog (DDOG) with a target of $160, indicating a 45.69% upside. Analysts from DBS, Chardan Capital, and Jefferies maintain these ratings, reflecting confidence in their growth potential. For more insights, TipRanks provides real-time updates on analyst ratings and stock performance.

Tip Ranks

Datadog

Tradr 2X Long DDOG Daily ETF

Grab

3 'Strong Buy' Stocks to Buy Now, 2/13/2026, According to Top Analysts

CFRA maintains a Hold opinion on Alnylam Pharmaceuticals, lowering its target price to $340 from $422 after reviewing Q4 results. The 2026 EPS forecast is reduced to $8.02 from $9.72, with a new 2027 EPS view of $11.97. Alnylam achieved GAAP profitability in 2025, driven by the successful launch of AMVUTTRA, leading to a significant revenue increase. Despite solid guidance for 2026, competition and pricing pressures in the ATTR-CM market are concerns.

fidelity

Research Alert: CFRA Keeps Hold Opinion On Shares Of Alnylam Pharmaceuticals, Inc.

Chardan Capital has maintained a Buy rating for Alnylam Pharma (ALNY) with a price target of $425. Analyst Keay Nakae, a 4-star analyst, has an average return of 4.6% and a 39.60% success rate. Additionally, TD Cowen's Ritu Baral also issued a Buy rating for Alnylam Pharma today. However, a Hold rating was reiterated by TipRanks on February 3.

Chardan Capital Sticks to Its Buy Rating for Alnylam Pharma (ALNY)

Alnylam Pharmaceuticals (ALNY) faces significant execution risks as it seeks to expand globally and achieve its 2030 growth ambitions, particularly with the commercialization of AMVUTTRA in ATTR-CM. The rapid increase in workforce and geographical reach is straining existing infrastructure, which could lead to delays in operational and regulatory capabilities, potentially disrupting product launches. The average stock price target for ALNY is $474.00, indicating a 53.66% upside potential.

Execution Risks Loom as Alnylam Races to Scale Global Operations for AMVUTTRA and 2030 Growth Ambitions

Alnylam Pharmaceuticals received a Buy rating from analyst Ritu Baral of TD Cowen, with a price target of $482. The rating is supported by Amvuttra's strong commercial performance and the company's transition to sustained profitability. Factors contributing to this outlook include revenue growth, increased cardiomyopathy penetration, and high treatment adherence. Alnylam's guidance for double-digit revenue growth through 2030 and a path to attractive operating margins further justify the Buy recommendation. Baral is recognized as a top analyst with a 39.7% average return.

Alnylam Pharmaceuticals: Amvuttra-Driven Profitability Inflection Supports Long-Term Growth and Buy Rating

AbbVie Inc. (ABBV) shares rose 2.99% to $227.50 on a challenging trading day, outperforming competitors like Johnson & Johnson and Pfizer. The stock ended a three-day losing streak but remains 7.07% below its 52-week high of $244.81. The S&P 500 fell 1.57% and the Dow Jones dropped 1.34%. Trading volume reached 8.7 million, surpassing the 50-day average of 6.5 million.

- AbbVie Inc. (ABBV) shares increased by 2.99% to $227.50 on a day when the broader market declined, with the S&P 500 and Dow Jones dropping significantly.  
- The stock ended a three-day losing streak but remained 7.07% below its 52-week high of $244.81 reached on October 1st.  
- Trading volume for AbbVie was 8.7 million shares, surpassing the 50-day average of 6.5 million, outperforming competitors like Johnson & Johnson and Pfizer.

AbbVie Inc. Stock Outperforms Competitors On Strong Trading Day

Eli Lilly & Co. (LLY) shares rose 2.27% to $1,038.27 on a day when the overall stock market declined, with the S&P 500 down 1.57% and the Dow Jones down 1.34%. This increase ended a three-day losing streak for Eli Lilly, although the stock remains 8.44% below its 52-week high of $1,133.95. In comparison, Johnson & Johnson rose 1.53%, Pfizer fell 0.94%, and AbbVie rose 2.99%. Trading volume was 3.6 million, surpassing the 50-day average of 3.2 million.

Defiance Daily Target 2X Long LLY ETF

Eli Lilly & Co. Stock Outperforms Competitors On Strong Trading Day

Direxion Daily Biotech Top 5 Bull 2X ETF(TBXU.US)

Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer | PFE Stock News

Entera Bio appoints Geno J. Germano as Chairman with Pfizer experience, advancing programs towards 2026 milestones.

Best Pharmaceutical Stocks To Keep An Eye On - February 14th

Alnylam Pharmaceuticals (NASDAQ:ALNY) Lowered to "Buy" Rating by Wall Street Zen

Daiwa downgrades Pfizer (PFE) to neutral following full-year 2025 earnings